March 15th, 2013
FDA Studying Whether Certain Diabetes Drugs Pose Pre-Cancer Risk
The FDA is investigating whether diabetes drugs in the class known as incretin mimetics pose an increased risk for pancreatic duct metaplasia. The agency is looking at unpublished data on pancreatic toxicity in a small number of tissue samples taken from patients with diabetes who died. It will examine the researchers’ methodology and the samples firsthand […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?